Phesi and Sensyne Health Collaborate to Advance Development of Synthetic Arms in Trials
Phesi Inc. has announced it has entered into a collaboration with clinical AI technology company, Sensyne Health, which is making an equity investment of $10 million in Phesi. The investment will be used to accelerate Phesi’s and Sensyne’s product roadmaps.
For Phesi this means further development of its trial planning, protocol design and investigator site selection platform, featuring ClinSite. For Sensyne, this means the growth and ‘industrialization’ of its data platform and forms part of the company’s US market growth strategy. The collaboration will see Sensyne anonymized real-world evidence data set of 6.1 million patients analyzed alongside Phesi’s data, which today covers 30 million clinical trial subjects.
Together, the companies will provide an enhanced offering of clinical trial and real-world data predictive analytics, enabling life sciences organizations to quickly and safely determine the feasibility of replacing or supplementing a comparator or placebo arm with a synthetic arm.
The agreement between Phesi and Sensyne Health was completed on January 4th, 2021; Dr Gen Li, Phesi’s CEO and Founder, also becomes a strategic advisor to the Board of Sensyne.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
